Pamorelin LA 3.75 mg poudre et solvant pour suspension injectable à libération prolongée スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

pamorelin la 3.75 mg poudre et solvant pour suspension injectable à libération prolongée

debiopharm research & manufacturing sa - triptorelinum - poudre et solvant pour suspension injectable à libération prolongée - praeparatio cryodesiccata: triptorelinum 3.75 mg ut triptorelini embonas, poly(lactidum-co-glycolidum), mannitolum, carmellosum natricum corresp. natrium 2.2 mg, polysorbatum 80, pro vitro. solvens: aqua ad iniectabile 2 ml. - analogo sintetico del gnrh / lhrh - synthetika

Votubia 5 mg Compresse スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

votubia 5 mg compresse

novartis pharma schweiz ag - everolimusum - compresse - everolimusum 5 mg, magnesii stearas, lactosum monohydricum 4.9 mg, hypromellosum, crospovidonum, lactosum 143.75 mg, e 321 pro compresso. - la sclerosi tuberosa - synthetika

Votubia 10 mg Compresse スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

votubia 10 mg compresse

novartis pharma schweiz ag - everolimusum - compresse - everolimusum 10 mg, lactosum 287.50 mg, crospovidonum, hypromellosum, lactosum monohydricum 9.8 mg, magnesii stearas, e 321 pro compresso. - la sclerosi tuberosa - synthetika

Votubia 2 mg dispergierbare Compresse スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

votubia 2 mg dispergierbare compresse

novartis pharma schweiz ag - everolimusum - dispergierbare compresse - everolimusum 2 mg, lactosum monohydricum 1.96 mg, hypromellosum, mannitolum, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, e 321 pro compresso. - la sclerosi tuberosa - synthetika

Votubia 3 mg dispergierbare Compresse スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

votubia 3 mg dispergierbare compresse

novartis pharma schweiz ag - everolimusum - dispergierbare compresse - everolimusum 3 mg, lactosum monohydricum 2.94 mg, hypromellosum, mannitolum, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, e 321 pro compresso. - la sclerosi tuberosa - synthetika

Votubia 5 mg dispergierbare Compresse スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

votubia 5 mg dispergierbare compresse

novartis pharma schweiz ag - everolimusum - dispergierbare compresse - everolimusum 5 mg, lactosum monohydricum 4.90 mg, hypromellosum, mannitolum, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, e 321 pro compresso. - la sclerosi tuberosa - synthetika

Everolimus-Teva 2.5 mg Compresse スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

everolimus-teva 2.5 mg compresse

teva pharma ag - everolimusum - compresse - everolimusum 2.5 mg, hypromellosum, lactosum monohydricum 4.9 mg, lactosum 69.425 mg, crospovidonum, magnesio stearas, e 321, pro compresso. - in combinazione con exemestane nelle donne in postmenopausa con carcinoma, hormonrezeptor positivo, her 2 negativo di cancro al seno dopo l'insuccesso di anastrozolo letrozolo o / a economie avanzate, progredienten, bene o moderatamente differenziati tumori neuroendocrini pancreatici origine / con carcinoma renale metastatico, dopo fallimento di sunitinib o sorafenib - biotechnologika

Everolimus-Teva 5 mg Compresse スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

everolimus-teva 5 mg compresse

teva pharma ag - everolimusum - compresse - everolimusum 5 mg, hypromellosum, lactosum monohydricum 9,8 mg, lactosum 138.85 mg, crospovidonum, magnesio stearas, e 321, pro compresso. - in combinazione con exemestane nelle donne in postmenopausa con carcinoma, hormonrezeptor positivo, her 2 negativo di cancro al seno dopo l'insuccesso di anastrozolo letrozolo o / a economie avanzate, progredienten, bene o moderatamente differenziati tumori neuroendocrini pancreatici origine / con carcinoma renale metastatico, dopo fallimento di sunitinib o sorafenib - biotechnologika

Everolimus-Teva 10 mg Compresse スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

everolimus-teva 10 mg compresse

teva pharma ag - everolimusum - compresse - everolimusum 10 mg, hypromellosum, lactosum monohydricum 19.6 mg, lactosum 277.7 mg, crospovidonum, magnesio stearas, e 321, pro compresso. - in combinazione con exemestane nelle donne in postmenopausa con carcinoma, hormonrezeptor positivo, her 2 negativo di cancro al seno dopo l'insuccesso di anastrozolo letrozolo o / a economie avanzate, progredienten, bene o moderatamente differenziati tumori neuroendocrini pancreatici origine / con carcinoma renale metastatico, dopo fallimento di sunitinib o sorafenib - biotechnologika

Verzenios 欧州連合 - イタリア語 - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - neoplasie al seno - agenti antineoplastici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.